CTMX Sean A Mccarthy sells $462K worth of shares
Nov 11, 2025, 5:35 AM
0.00%
What does CTMX do
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
Sean A Mccarthy sold 101,793 shares of CTMX on 6 November at $4.54 per share, worth a total of $462K. They now own 987,891 CTMX shares, or a 9% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.